BSX Stock Analysis — Boston Scientific
Sector: Healthcare
AI Verdict
Boston Scientific is cheap for the growth you're getting, but the market is clearly pricing in skepticism that the turnaround will stick despite the company's entrenched position in hospital systems.
Competitive Moat
Boston Scientific designs and manufactures minimally invasive medical devices for cardiology, electrophysiology, and other specialties, with a defensible position due to its broad patent portfolio and deep integration into hospital purchasing systems. Its recurring revenue from consumables and regulatory expertise make it hard for new entrants to displace.
Summary
RSI at 19.8 signals extreme oversold territory after a -59.52% one-year return, despite a sharp earnings growth forecast.
Where It Stands
Boston Scientific trades at 12.9x next year's earnings—well below the healthcare sector median of 22x—while analysts expect 41.0% EPS growth and the RSI of 19.8 points to severe overselling.
Key Metrics
- RSI: 19.8 — Oversold
- Trailing P/E: 18.2x
- Forward P/E: 12.9x
- PEG Ratio: 0.45
- Earnings Growth: +0.4%
- Revenue Growth: +0.2%
- Market Cap: $64.6B
- 1-Year Return: -59.52%
- 52-Week High: $109.50
- 52-Week Low: $43.37
Analyst Consensus
32 Buy · 8 Hold · 0 Sell (40 analysts)
Bull Case
With a forward P/E of 12.9x and 41.0% expected EPS growth, you're paying a bargain price for rapid earnings acceleration if the moat holds.
Bear Case
If the P/E multiple reverts further or growth disappoints, another 20–30% drop is plausible given the already brutal -59.52% one-year return and deeply oversold RSI.
Catalyst to Watch
Watch for upcoming FDA approvals or clinical trial results—positive data could quickly reverse the oversold sentiment.